Keros Therapeutics (KROS) Total Liabilities (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Total Liabilities data on file, last reported at $34.9 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 21.3% year-over-year to $34.9 million; the trailing twelve-month figure through Dec 2025 stood at $34.9 million (down 21.3% YoY), and the FY2025 full-year result was $34.9 million, down 21.3% from the prior year.
• Total Liabilities for Q4 2025 stood at $34.9 million, down from $39.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $55.7 million in Q1 2025 and bottomed at $7.8 million in Q2 2021.
• The 5-year median for Total Liabilities is $30.2 million (2023), against an average of $28.7 million.
• The widest annual swing landed in 2023, when Total Liabilities soared 163.82%; it then declined 21.3% in 2025.
• A 5-year view of Total Liabilities shows it stood at $12.1 million in 2021, then soared by 143.09% to $29.4 million in 2022, then advanced by 28.8% to $37.8 million in 2023, then rose by 17.25% to $44.3 million in 2024, then slipped by 21.3% to $34.9 million in 2025.
• The last three Total Liabilities figures came in at $34.9 million (Q4 2025), $39.2 million (Q3 2025), and $50.4 million (Q2 2025), per Business Quant data.

Peer Comparison